The early and efficient assessment of cardiac safety liabilities is essential to confidently
advance novel drug candidates. This article discusses evolving mechanistically based …

Induced pluripotent stem cells (iPSCs) are reprogrammed cells that have features similar to
embryonic stem cells, such as the capacity of self-renewal and differentiation into many …

Directed differentiation protocols enable derivation of cardiomyocytes from human
pluripotent stem cells (hPSCs) and permit engineering of human myocardium in vitro …

Human pluripotent stem cell-derived cardiomyocytes (hPS-CM) may offer a number of
advantages over previous cardiac models, however, questions of their immaturity complicate …

Drugs targeting atrial‐specific ion channels, Kv1. 5 or Kir3. 1/3.4, are being developed as
new therapeutic strategies for atrial fibrillation. However, current preclinical studies carried …

Conductive and electroactive polymers have the potential to enhance engineered cardiac
tissue function. In this study, an interpenetrating network of the electrically-conductive …

Aim There is now compelling evidence that cells committed to a cardiac lineage are most
effective for improving the function of infarcted hearts. This has been confirmed by our pre …

Predicting human safety risks of novel xenobiotics remains a major challenge, partly due to
the limited availability of human cells to evaluate tissue-specific toxicity. Recent progress in …

Translation of novel therapies from bench to bedside is hampered by profound disparities
between animal and human genetics and physiology. The ability to test for efficacy and …

Human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) are the most promising
source of cardiomyocytes (CMs) for experimental and clinical applications, but their use is …